CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that scientists have named the company one of the most highly regarded employers in the biopharmaceutical industry. In a survey commissioned by Science and the American Association for the Advancement of Science, Genzyme ranked among 20 companies in the industry with the best reputations as employers. Genzyme was recognized in particular for valuing and respecting its scientists, for its social responsibility, and for doing important, quality research.
This is the 10th consecutive year that Genzyme has earned this distinction.
“We continue to foster an environment of interconnectivity within our R&D organization, in which all employees have a shared focus on discovering and developing medicines to make a difference in patients’ lives,” said Rich Gregory, Senior Vice President and Head of the Sanofi-Genzyme R&D Center.
More than 4,000 Science readers globally participated in the survey. Fifty-six percent of respondents work in biotechnology and 35 percent for a pharmaceutical company. Twenty-three percent of respondents reported working in basic research, 30 percent in applied research, and 30 percent in development. Seventy-eight percent of respondents were based in North America, 14 percent in Europe, and 5 percent in the Asia/Pacific Rim.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Ingrid Esser, 617-768-6699